Becton Dickinson and Company (BDX)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)
BDX
Becton Dickinson and Company
$151.16
+1.07%
HEALTHCARE · Cap: $39.80B
NNNN
Anbio Biotechnology Class A Ordinary Shares
$22.99
-14.88%
HEALTHCARE · Cap: $684.26M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 256955% more annual revenue ($22.23B vs $8.65M). NNNN leads profitability with a 74.1% profit margin vs 5.1%. BDX trades at a lower P/E of 25.2x. BDX earns a higher WallStSmart Score of 65/100 (B-).
BDX
Strong Buy65
out of 100
Grade: B-
NNNN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+9.9%
Fair Value
$200.45
Current Price
$151.16
$49.29 discount
Intrinsic value data unavailable for NNNN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Every $100 of equity generates 32 in profit
Keeps 74 of every $100 in revenue as profit
Strong operational efficiency at 59.1%
Revenue surging 73.9% year-over-year
Areas to Watch
Moderate valuation
ROE of 4.7% — below average capital efficiency
5.1% margin — thin
Distress zone — elevated risk
2.8% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Trading at 33.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bull Case : NNNN
The strongest argument for NNNN centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 74.1% and operating margin at 59.1%. Revenue growth of 73.9% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin.
Bear Case : NNNN
The primary concerns for NNNN are EPS Growth, Market Cap, P/E Ratio. A P/E of 103.9x leaves little room for execution misses.
Key Dynamics to Monitor
BDX profiles as a value stock while NNNN is a growth play — different risk/reward profiles.
NNNN is growing revenue faster at 73.9% — sustainability is the question.
BDX generates stronger free cash flow (546M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BDX scores higher overall (65/100 vs 52/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Anbio Biotechnology Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?